Enanta Pharmaceuticals, Inc. Announces Detailed Data From TURQUOISE-II Study In Chronic Hepatitis C Patients With Cirrhosis Being Presented At The European Association For The Study Of The Liver (EASL) Meeting
4/14/2014 9:41:13 AM
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that detailed results from AbbVie’s pivotal phase 3 TURQUOISE-II study, will be presented as a late-breaking oral presentation today at the International Liver Congress (ILC), which is the 49th Annual Meeting of the European Association for the Study of the Liver (EASL). Results from the TURQUOISE-II study were featured in the ILC press conference yesterday and were published on-line in the New England Journal of Medicine.
Help employers find you! Check out all the jobs and post your resume.
comments powered by